15.96
0.45 (2.90%)
| Previous Close | 15.51 |
| Open | 15.84 |
| Volume | 1,125,416 |
| Avg. Volume (3M) | 1,852,062 |
| Market Cap | 2,204,076,032 |
| Price / Earnings (Forward) | 111.11 |
| Price / Sales | 3.92 |
| Price / Book | 3.39 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 - 11 Aug 2025 |
| Profit Margin | -26.41% |
| Operating Margin (TTM) | 70.24% |
| Diluted EPS (TTM) | -1.24 |
| Quarterly Revenue Growth (YOY) | -29.60% |
| Total Debt/Equity (MRQ) | 108.23% |
| Current Ratio (MRQ) | 5.15 |
| Operating Cash Flow (TTM) | 61.15 M |
| Levered Free Cash Flow (TTM) | -6.46 M |
| Return on Assets (TTM) | -5.86% |
| Return on Equity (TTM) | -26.22% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Arrowhead Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 2.0 |
| Average | 2.13 |
|
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 13.02% |
| % Held by Institutions | 77.19% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 80.00 (HC Wainwright & Co., 401.25%) | Buy |
| Median | 60.00 (275.94%) | |
| Low | 17.00 (Citigroup, 6.52%) | Hold |
| Average | 52.33 (227.88%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 15.62 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 20 May 2025 | 80.00 (401.25%) | Buy | 16.29 |
| Chardan Capital | 13 May 2025 | 60.00 (275.94%) | Buy | 15.28 |
| Citigroup | 13 May 2025 | 17.00 (6.52%) | Hold | 15.28 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 08 Jul 2025 | Announcement | Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia |
| 23 Jun 2025 | Announcement | Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran |
| 02 Jun 2025 | Announcement | Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity |
| 29 May 2025 | Announcement | Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences |
| 12 May 2025 | Announcement | Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results |
| 07 May 2025 | Announcement | Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences |
| 30 Apr 2025 | Announcement | Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results |
| 15 Apr 2025 | Announcement | Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |